ClinicalTrials.gg
CompletedNCT00914927Updated Jan 23, 2018Results posted

Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures

A Phase 2 interventional study of Avatrombopag and Avatrombopag in Thrombocytopenia Related to Chronic Liver Disease, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-23.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing avatrombopag in Thrombocytopenia — 6 open to participants now, 6 under way, 2 of them phase 3. avatrombopag · Thrombocytopenia.

Enrollment
7th of 23
130 · median 50
Started
2009
the only one that year
Phase 2
10 of 23
3 open now
Registered
1st of 23
by date
Lead sponsor
5 of 23
Eisai Inc.

Among the 23 studies testing avatrombopag in Thrombocytopenia, this one is the 7th largest by enrollment, is the only one that started in 2009, is one of 10 in phase 2, and was the 1st registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

6 of the 23 studies testing avatrombopag in Thrombocytopenia are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About avatrombopag

avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing avatrombopag in Thrombocytopenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of once-daily Oral avatrombopagin subjects with chronic liver diseases and thrombocytopenia prior to elective surgical or diagnostic procedures, to evaluate the safety of short-term administration of avatrombopag and to evaluate the pharmacokinetics (PK) of E5501.

03

Conditions studied

  • Thrombocytopenia Related to Chronic Liver Disease

Browse trials for

Keywords

  • Thrombocytopenia
  • chronic liver disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Males or females ≥ 18 years of age
  2. Thrombocytopenia (defined as a count ≥ 10,000 - ≤ 50,000 (+15%)/mm\^3 )
  3. Model for End-Stage Liver Disease (MELD) scores ≤ 24
  4. Chronic liver diseases due to one of the following three etiologies:

    Chronic Viral Hepatitis from one of the following categories

    • Chronic (defined as the presence of anti-hepatitis C virus [HCV] antibodies and/or detectable serum HCV ribonucleic acid [RNA] levels)
    • OR chronic (defined as the presence of hepatitis B surface antigen [HBsAg] and/or detectable serum hepatitis B virus [HBV] deoxyribonucleic acid [DNA])
    • OR chronic Hepatitis B and C co-infection (as defined by the above bullet points)
    • OR chronic Hepatitis C and history of alcohol abuse
    • OR chronic Hepatitis B and history of alcohol abuse

    NASH diagnosed as:

    • absence of serologic evidence of viral hepatitis and
    • convincing evidence of a history of minimal or no alcohol consumption, and
    • histologic picture of steatohepatitis OR
    • when histology is unavailable, then clinical, radiographic and laboratory evidence of NASH

    Alcoholic liver disease diagnosed as:

    • absence of serologic evidence of viral hepatitis and
    • history of heavy alcohol consumption and
    • histologic picture of alcoholic liver disease OR
    • when histology is unavailable, then clinical, radiographic and laboratory evidence of hepatitis combined with years of excessive alcohol intake
  5. Subjects who are scheduled to undergo an elective invasive procedure between 1 to 4 days post last dose of study drug.
  6. Adequate renal function as evidenced by a calculated ≥50 mL/minute per the Cockcroft and Gault formula
  7. ≥3 months

Key Exclusion Criteria:

  1. Hepatic encephalopathy that cannot be effectively treated.
  2. Platelet transfusion within 7 days prior to the first dose of study drug
  3. Received blood products, eg, FFP and cryoprecipitate 7 days prior to the first dose of study drug
  4. Have surgical or diagnostic procedure scheduled during the Randomization Phase (Day 1 to Day 8) of this study
  5. Interferon use within 2 weeks of Day 1
  6. Hormonal use within 60 days of study entry
  7. History of (HIV) infection
  8. Any prohibited concomitant medications or therapy that cannot be discontinued by Visit 1
  9. Active alcohol abuse, active alcohol dependence syndrome, drug abuse, or drug dependence within 6 months of the study start (unless participating in a controlled rehabilitation program)
  10. Acute alcoholic hepatitis (chronic alcoholic hepatitis is allowed) within 6 months of the study start
  11. History of any primary hematologic disorder
  12. History of arterial or venous thrombosis, including thrombosis of any part of the splenic-mesenteric system
  13. Any evidence of current portal vein thrombosis (PVT) as detected by Doppler sonography or appropriate MRI/CT imaging at Screening and/or within approximately 30 days prior to Screening
  14. Any acute/active bleeding (gastrointestinal [GI], central nervous system [CNS], etc)
  15. Uncompensated congestive heart failure ( [NYHA] Class III or IV)
  16. Pre-diagnosed Immune Thrombocytopenic Purpura (ITP)
  17. History of Myelodysplastic Syndrome (MDS)
  18. Females who are pregnant (positive β-hCG test ) or breastfeeding
  19. Current use of recreational drugs
  20. Post-transplant patients
  21. Subjects who have participated in another trial within 30 days prior to Visit 1.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    1

    Drug: Avatrombopag

  • Experimental
    2

    Drug: Avatrombopag · Drug: Placebo

  • Placebo comparator
    3

    Drug: Placebo

Interventions

  • Avatrombopag first Dose 80 mg followed by 10 mg a day for up to 6 additional days

  • Avatrombopag first Dose 80 mg followed by 20 mg a day for 3 days and then Placebo for 3 additional days

  • DrugPlacebo

    Placebo or inactive substance once a day for up to 7 days

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Response

    Platelet counts (PC) were determined from blood draws. A responder is defined as a participant having an increase of at least 20,000/mm\^3 PC from Baseline and a PC greater than 50,000/mm\^3 at least once during Day 4 through Day 8. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (end of treatment (EOT)), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.

    Time frame: Day 8 (Visit 5, EOT)

Secondary outcomes

  1. Change in Platelet Count on Day 8 (Visit 5 and/or End of Treatment) From Baseline

    Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.

    Time frame: Day 8 (Visit 5, EOT)

  2. Percentage of Participants Experiencing Dose-response by Visit

    Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.

    Time frame: Day 4 (Visit 3), Day 6 ( Visit 4), Day 8 (Visit 5, EOT), 3 Day Post Last Dose (Visit 6), and 7 Day Post Last Dose (Visit 7)

  3. Percentage of Participants Who Achieved a Platelet Count Greater Than 75,000/mm^3 on Day 4

    Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.

    Time frame: Day 4 (Visit 3)

  4. Percentage of Participants Who Achieved a Platelet Count Greater Than 100,000/mm^3 on Days 4 and 8

    Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.

    Time frame: Day 4 (Visit 3) and Day 8 (Visit 5, EOT)

07

Results

Posted Jan 23, 2018

Participant flow

Participant flow — Overall Study
MilestoneCohort A: 20 mg Avatrombopag, 1G FormulationCohort A: 40 mg Avatrombopag, 1G FormulationCohort A: 80 mg Avatrombopag, 1G FormulationCohort A: Placebo, 1G FormulationCohort B: 0 mg Avatrombopag, 2G FormulationCohort B: 20 mg Avatrombopag, 2G FormulationCohort B: Placebo, 2G Formulation
Started18161716212121
Completed16141714192121
Not completed2202200
Withdrew: Adverse event0000100
Withdrew: Withdrawal by subject0101000
Withdrew: Lost to follow-up0001000
Withdrew: Administrative/other2100100

Outcome measures

PrimaryPercentage of Participants Experiencing Response

Platelet counts (PC) were determined from blood draws. A responder is defined as a participant having an increase of at least 20,000/mm\^3 PC from Baseline and a PC greater than 50,000/mm\^3 at least once during Day 4 through Day 8. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (end of treatment (EOT)), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.

Time frame:
Day 8 (Visit 5, EOT)
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing Response
Percentage of participantsCohort A: 20 mg Avatrombopag, 1G FormulationCohort A: 40 mg Avatrombopag , 1G FormulationCohort A: 80 mg Avatrombopag, 1G FormulationCohort A: Placebo, 1G FormulationCohort B:10 mg Avatrombopag, 2G FormulationCohort B: 20 mg Avatrombopag, 2G FormulationCohort B: Placebo, 2G Formulation
Yes response38.931.376.56.342.952.49.5
No response61.168.823.593.857.147.690.5
SecondaryChange in Platelet Count on Day 8 (Visit 5 and/or End of Treatment) From Baseline

Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.

Time frame:
Day 8 (Visit 5, EOT)
Reported as:
Mean · K/mm^3
Change in Platelet Count on Day 8 (Visit 5 and/or End of Treatment) From Baseline
K/mm^3Cohort A: 20 mg Aavatrombopag, 1G FormulationCohort A: 40 mg Avatrombopag, 1G FormulationCohort A: 80 mg Avatrombopag, 1G FormulationCohort A: Placebo, 1G FormulationCohort B: 10 mg Avatrombopag, 2G FormulationCohort B: 20 mg Aavatrombopag, 2G FormulationCohort B: Placebo, 2G Formulation
Change in Platelet Count on Day 8 (Visit 5 and/or End of Treatment) From Baseline16.2 ± 10.3215.9 ± 13.4532.2 ± 18.593.1 ± 17.9718.9 ± 10.0724.9 ± 17.913.9 ± 12.49
SecondaryPercentage of Participants Experiencing Dose-response by Visit

Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.

Time frame:
Day 4 (Visit 3), Day 6 ( Visit 4), Day 8 (Visit 5, EOT), 3 Day Post Last Dose (Visit 6), and 7 Day Post Last Dose (Visit 7)
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing Dose-response by Visit
Percentage of participantsCohort A: 20 mg Avatrombopag, 1G FormulationCohort A:40 mg Avatrombopag, 1G FormulationCohort A: 80 mg Avatrombopag, 1G FormulationCohort A: Placebo, 1G FormulationCohort B: 10 mg Avatrombopag, 2G FormulationCohort B: 20 mg Avatrombopag, 2G FormulationCohort B: Placebo, 2G Formulation
Yes response (Day 4, Visit 3)005.9004.84.8
No response (Day 4, Visit 3)100.0100.094.1100.0100.095.295.2
Yes response (Day 6, Visit 4)11.112.529.4014.333.39.5
No response (Day 6, Visit 4)88.987.570.6100.085.766.790.5
Yes response (Day 8, Visit 5)38.931.376.56.342.952.49.5
No response (Day 8, Visit 5)61.168.823.593.857.147.690.5
Yes response (3 Day post last dose, Visit 6)55.656.382.412.566.761.99.5
No response (3 Day post last dose, Visit 6)44.443.817.687.533.338.190.5
Yes response (7 Day post last dose, Visit 7)61.162.588.212.571.461.99.5
No response (7 Day post last dose, Visit 7)38.937.511.887.528.638.190.5
SecondaryPercentage of Participants Who Achieved a Platelet Count Greater Than 75,000/mm^3 on Day 4

Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.

Time frame:
Day 4 (Visit 3)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a Platelet Count Greater Than 75,000/mm^3 on Day 4
Percentage of participantsCohort A: 20 mg Avatrombopag, IG FormulationCohort A: 40 mg Avatrombopag, IG FormulationCohort A: 80 mg Avatrombopag, IG FormulationCohort A: Placebo, IG FormulationCohort B: 10 mg Avatrombopag, 2G FormulationCohort B: 20 mg Avatrombopag, 2G FormulationCohort B: Placebo, 2G Formulation
Yes response5.6000000
No response94.4100.0100.0100.0100.0100.0100.0
SecondaryPercentage of Participants Who Achieved a Platelet Count Greater Than 100,000/mm^3 on Days 4 and 8

Platelet counts were determined from blood draws. Missing PC assessments at any given time point was considered to be a non-response at that point and were not estimated. For PC measurements taken after the last dose day (EOT), the postdose windows applied. If there was more than one PC within the same analysis visit window, the following selection rules were applied sequentially to determine which PC was used for that time point: 1) the PC that was closer to the target date was used, 2) if PC were equal-distance in days from the target day, the later one based on measurement date and time was used, and 3) if there was more than one PC on the same day, if it was a baseline record, the largest one was used; if it was a postbaseline record, the smallest one was used.

Time frame:
Day 4 (Visit 3) and Day 8 (Visit 5, EOT)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a Platelet Count Greater Than 100,000/mm^3 on Days 4 and 8
Percentage of participantsCohort A: 20 mg Avatrombopag, 1G FormulationCohort A: 40 mg Avatrombopag, 1G FormulationCohort A: 80 mg Avatrombopag, 1G FormulationCohort A: Placebo, 1G FormulationCohort B: 10 mg Avatrombopag, 2G FormulationCohort B: 20 mg Avatrombopag, 2G FormulationCohort B: Placebo, 2G Formulation
Yes response (Day 4, Visit 3)5.6000000
No response (Day 4, Visit 3)94.4100.0100.0100.0100.0100.0100.0
Yes response (Day 8, Visit 5)5.6011.804.89.50
No response (Day 8, Visit 5)94.4100.088.2100.095.290.5100.0

Adverse events

Collected over Approximately 44 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: 20 mg Avatrombopag, 1G Formulation0/18 (0%)3/18 (16.7%)17/18 (94.4%)
Cohort A: 40 mg Avatrombopag, 1G Formulation0/16 (0%)2/16 (12.5%)13/16 (81.3%)
Cohort A: 80 mg Avatrombopag, 1G Formulation0/17 (0%)3/17 (17.6%)13/17 (76.5%)
Cohort A: Placebo, 1G Formulation0/16 (0%)1/16 (6.3%)12/16 (75%)
Cohort B: 10 mg Avatrombopag, 2G Formulation1/21 (4.8%)5/21 (23.8%)17/21 (81%)
Cohort B: 20 mg Avatrombopag, 2G Formulation0/21 (0%)3/21 (14.3%)18/21 (85.7%)
Cohort B: Placebo, 2G Formulation0/21 (0%)3/21 (14.3%)16/21 (76.2%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventCohort A: 20 mg Avatrombopag, 1G FormulationCohort A: 40 mg Avatrombopag, 1G FormulationCohort A: 80 mg Avatrombopag, 1G FormulationCohort A: Placebo, 1G FormulationCohort B: 10 mg Avatrombopag, 2G FormulationCohort B: 20 mg Avatrombopag, 2G FormulationCohort B: Placebo, 2G Formulation
CellulitisInfections and infestations0/180/160/171/161/210/210/21
SeromaInjury, poisoning and procedural complications0/181/160/170/160/210/210/21
Acute prerenal failureRenal and urinary disorders0/181/160/170/160/210/210/21
Gastric haemorrhageGastrointestinal disorders0/180/161/170/160/210/210/21
Liver disorderHepatobiliary disorders0/180/161/170/161/210/210/21
Portal vein thrombosisHepatobiliary disorders0/180/161/170/160/210/210/21
AnaemiaBlood and lymphatic system disorders1/180/160/170/160/210/210/21
Upper gastrointestinal haemorrhageGastrointestinal disorders1/180/160/170/160/210/210/21
PneumoniaInfections and infestations1/180/160/170/160/210/210/21
Intentional overdoseInjury, poisoning and procedural complications1/180/160/170/160/210/210/21
Most frequent other events
Showing 10 of 147
Most frequent other events
EventCohort A: 20 mg Avatrombopag, 1G FormulationCohort A: 40 mg Avatrombopag, 1G FormulationCohort A: 80 mg Avatrombopag, 1G FormulationCohort A: Placebo, 1G FormulationCohort B: 10 mg Avatrombopag, 2G FormulationCohort B: 20 mg Avatrombopag, 2G FormulationCohort B: Placebo, 2G Formulation
NauseaGastrointestinal disorders1/182/162/172/165/212/213/21
Abdominal pain upperGastrointestinal disorders4/181/161/170/160/210/210/21
Portal hypertensive gastropathyGastrointestinal disorders4/182/160/170/163/210/212/21
FatigueGeneral disorders4/181/160/171/162/212/214/21
VomitingGastrointestinal disorders1/182/163/170/160/211/211/21
Abdominal painGastrointestinal disorders1/181/160/171/162/210/213/21
AscitesGastrointestinal disorders1/181/161/170/160/211/213/21
DiarrhoeaGastrointestinal disorders2/181/161/170/160/213/212/21
PyrexiaGeneral disorders0/180/162/172/161/210/213/21
DizzinessNervous system disorders2/180/161/171/163/211/211/21

Baseline characteristics

Intent to Treat (ITT) population included all participants who were randomized into the study, received study medication, and had a post-treatment assessment.

Age, Continuous
Age, Continuous(Years)Cohort A: 20 mg Avatrombopag, 1G FormulationCohort A: 40 mg Avatrombopag, 1G FormulationCohort A: 80 mg Avatrombopag, 1G FormulationCohort A: Placebo, 1G FormulationCohort B: 10 mg Avatrombopag, 2G FormulationCohort B: 20 mg Avatrombopag, 2G FormulationCohort B: Placebo, 2G FormulationTotal
Mean55.3 ± 7.1652.8 ± 7.7855.2 ± 5.9654.2 ± 6.8753.9 ± 5.4856.8 ± 6.4655.6 ± 6.5254.8 ± 6.56
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: 20 mg Avatrombopag, 1G FormulationCohort A: 40 mg Avatrombopag, 1G FormulationCohort A: 80 mg Avatrombopag, 1G FormulationCohort A: Placebo, 1G FormulationCohort B: 10 mg Avatrombopag, 2G FormulationCohort B: 20 mg Avatrombopag, 2G FormulationCohort B: Placebo, 2G FormulationTotal
Female4365107742
Male1413111111141488
08

Study locations

1 site
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Nov 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2018, 6 years 2 months after primary completion. A results delay was requested in May 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2009
First posted
Jun 5, 2009
Start
May 2009
Primary completionActual
Nov 11, 2011
CompletionActual
Dec 21, 2011
Results delay requested
May 21, 2013
Results first posted
Jan 23, 2018
Last update
Jan 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00914927
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jun 5, 2009
Start date
May 2009
Primary completion
Nov 11, 2011
Completion
Dec 21, 2011
Results posted
Jan 23, 2018
Last update
Jan 23, 2018

Study contacts

Tim Jenkins
study director · Eisai Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avatrombopag

Start the discussion